Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
OBX
Obsidian Therapeutics, Inc.
CAPPED RATING
Obsidian Therapeutics, Inc. (OBX) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (F).
Quantitative Factor Evaluation • Updated
Overall Rating
1.8
/ 5.0
D+
Value
C+
Factor Score
2.5
/ 5.0
Growth
D+
Factor Score
1.8
/ 5.0
Profitability
F
Factor Score
0.4
/ 5.0
Momentum
D+
Factor Score
1.8
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-5.9
EV / EBITDA
-11.2
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-29.8%
Price Return 12M
-28.7%
Catalyst Signal
0.00
Market Cap
$770.9M
TTM Revenue
N/A
Price / Sales
N/A
ROE
N/A
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | D+ (1.8) | F (0.4) | D+ (1.8) | C+ (2.6) | D+ (1.8) |
| 2026-11-06 | C+ (2.5) | D+ (1.8) | F (0.4) | D (1.3) | C+ (2.7) | D+ (1.8) |
| 2026-10-30 | C+ (2.5) | D+ (1.8) | F (0.5) | C (2.3) | C+ (2.7) | C- (2.0) |
| 2026-10-23 | C+ (2.5) | C- (1.9) | F (0.5) | C- (2.1) | C+ (2.6) | C- (1.9) |
| 2026-10-16 | C+ (2.5) | D+ (1.8) | F (0.5) | C (2.2) | C+ (2.6) | C- (1.9) |
Page
1
of
3